NKX2-1 and lymphoma: This interrelation suggests that enhancement of ectopic oncogene expression (e.g. NKX2-1 in DLBCL) may result in transdifferentiation of the lymphoma cells into benign non-hematopoietic cells, representing a novel concept for cancer therapy.